Natalia P Denisenko, Anastasia A Kachanova, Ivan V Sychev, Gregory N Shuev, Oksana M Perfilieva, Reis H Mukhamadiev, Ruslan E Kazakov, Olga I Milyutina, Olga V Konenkova, Sergey A Ryzhkin, Elena M Zhmaeva, Sergey L Kirienko, Dmitriy V Ivashchenko, Irina V Bure, Alexander S Ametov, Irina V Poddubnaya, Karin B Mirzaev, Dmitry A Sychev
{"title":"甲状腺癌症患者放射性碘治疗不良反应的遗传标志物。","authors":"Natalia P Denisenko, Anastasia A Kachanova, Ivan V Sychev, Gregory N Shuev, Oksana M Perfilieva, Reis H Mukhamadiev, Ruslan E Kazakov, Olga I Milyutina, Olga V Konenkova, Sergey A Ryzhkin, Elena M Zhmaeva, Sergey L Kirienko, Dmitriy V Ivashchenko, Irina V Bure, Alexander S Ametov, Irina V Poddubnaya, Karin B Mirzaev, Dmitry A Sychev","doi":"10.1515/dmpt-2023-0007","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients.</p><p><strong>Methods: </strong>The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. <i>NFKB1</i>, <i>ATM</i>, <i>ATG16L2</i>, <i>ATG10</i>, <i>TGFB1</i>, and <i>TNF</i> polymorphisms were determined by allele-specific realtime-PCR.</p><p><strong>Results: </strong>The frequency of adverse reactions was the following: gastrointestinal symptoms - 57.9 %, local symptoms - 65.8 %, cerebral symptoms - 46.8 %, fatigue - 54.4 %; signs of sialoadenitis six months after radioiodine therapy - 25.2 %. TT genotype carriers of <i>ATG10</i> rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of <i>ATG10</i> rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of <i>TGFB1</i> rs1800469 (vs. AG+GG). CC genotype of <i>ATG10</i> rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the <i>ATM</i> rs11212570 had a protective role against fatigue. <i>TGFB1</i> rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy.</p><p><strong>Conclusions: </strong>Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 3","pages":"255-265"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients.\",\"authors\":\"Natalia P Denisenko, Anastasia A Kachanova, Ivan V Sychev, Gregory N Shuev, Oksana M Perfilieva, Reis H Mukhamadiev, Ruslan E Kazakov, Olga I Milyutina, Olga V Konenkova, Sergey A Ryzhkin, Elena M Zhmaeva, Sergey L Kirienko, Dmitriy V Ivashchenko, Irina V Bure, Alexander S Ametov, Irina V Poddubnaya, Karin B Mirzaev, Dmitry A Sychev\",\"doi\":\"10.1515/dmpt-2023-0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients.</p><p><strong>Methods: </strong>The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. <i>NFKB1</i>, <i>ATM</i>, <i>ATG16L2</i>, <i>ATG10</i>, <i>TGFB1</i>, and <i>TNF</i> polymorphisms were determined by allele-specific realtime-PCR.</p><p><strong>Results: </strong>The frequency of adverse reactions was the following: gastrointestinal symptoms - 57.9 %, local symptoms - 65.8 %, cerebral symptoms - 46.8 %, fatigue - 54.4 %; signs of sialoadenitis six months after radioiodine therapy - 25.2 %. TT genotype carriers of <i>ATG10</i> rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of <i>ATG10</i> rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of <i>TGFB1</i> rs1800469 (vs. AG+GG). CC genotype of <i>ATG10</i> rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the <i>ATM</i> rs11212570 had a protective role against fatigue. <i>TGFB1</i> rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy.</p><p><strong>Conclusions: </strong>Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.</p>\",\"PeriodicalId\":11332,\"journal\":{\"name\":\"Drug metabolism and personalized therapy\",\"volume\":\"38 3\",\"pages\":\"255-265\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug metabolism and personalized therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/dmpt-2023-0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2023-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients.
Objectives: Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients.
Methods: The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. NFKB1, ATM, ATG16L2, ATG10, TGFB1, and TNF polymorphisms were determined by allele-specific realtime-PCR.
Results: The frequency of adverse reactions was the following: gastrointestinal symptoms - 57.9 %, local symptoms - 65.8 %, cerebral symptoms - 46.8 %, fatigue - 54.4 %; signs of sialoadenitis six months after radioiodine therapy - 25.2 %. TT genotype carriers of ATG10 rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of ATG10 rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of TGFB1 rs1800469 (vs. AG+GG). CC genotype of ATG10 rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the ATM rs11212570 had a protective role against fatigue. TGFB1 rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy.
Conclusions: Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.
期刊介绍：
Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
